Testing the abuse liability of anxiolytic and hypnotic drugs in humans.
about
Amphetamine-induced place preference in humansAssessment of single-dose benzodiazepines on insulin secretion, insulin sensitivity and glucose effectiveness in healthy volunteers: a double-blind, placebo-controlled, randomized cross-over trial [ISRCTN08745124]Bridging the gap between education and appropriate use of benzodiazepines in psychiatric clinical practiceDo initial responses to drugs predict future use or abuse?Effects of nicotine on attention and inhibitory control in healthy nonsmokers.Abuse liability assessment of tobacco products including potential reduced exposure productsThe safety and tolerability of zolpidem--an update.Abuse potential of carbohydrates for overweight carbohydrate craversEffects of delta 9-THC on marijuana smoking, dose choice, and verbal report of drug liking.Inhalation of Alcohol Vapor: Measurement and Implications.Quetiapine Misuse and Abuse: Is it an Atypical Paradigm of Drug Seeking Behavior?Modest abuse-related subjective effects of zolpidem in drug-naive volunteers.Principles of laboratory assessment of drug abuse liability and implications for clinical development.Abuse potential assessment of propofol by its subjective effects after sedationCharacterizing the subjective and psychomotor effects of carisoprodol in healthy volunteersDeath and dependence: current controversies over the selective serotonin reuptake inhibitors.Psychopharmacology of theobromine in healthy volunteers.An association study of the brain-derived neurotrophic factor Val66Met polymorphism and amphetamine responsePreference procedures for testing the abuse liability of drugs in humans.Abuse potential of propofol used for sedation in gastric endoscopy and its correlation with subject characteristics.Opioid abusers' ability to differentiate an opioid from placebo in laboratory challenge testing.Benzodiazepines revisited--will we ever learn?Memory dysfunction in panic disorder: an investigation of the role of chronic benzodiazepine use.Cannabidiol Does Not Dampen Responses to Emotional Stimuli in Healthy Adults.The effects of MDMA on socio-emotional processing: Does MDMA differ from other stimulants?Individual differences in responses to ethanol and d-amphetamine: a within-subject study.Effects of stress and alcohol on subjective state in humans.Reinforcing, subject-rated, performance and physiological effects of methylphenidate and d-amphetamine in stimulant abusing humans.Ethanol impairs saccadic and smooth pursuit eye movements without producing self-reports of sedation.Evaluation of the subjective and reinforcing effects of diphenhydramine, levetiracetam, and valproic acid.Zolpidem in insomnia: a 3-year post-marketing surveillance study in Switzerland.Healthy subjects with a family history of alcoholism show increased stimulative subjective effects of alcohol.Subjective and objective responses to ethanol in moderate/heavy and light social drinkers.Systemic absorption and abuse liability of snorted flunitrazepam.Naltrexone increases the latency to drink alcohol in social drinkers.
P2860
Q22252505-1DA233E6-A17B-43AA-9CF6-731C6CE597D3Q24805192-AA6625C2-E985-4D86-9123-6B909CC68B1AQ26800235-803D0051-C42C-4057-96B3-C7F99BB1E86FQ27025975-F93AD47A-AB4E-4B13-9226-7CC93376679AQ30422977-31686077-DEF0-420C-A9F1-90BD7B095A6AQ33559301-B2E2DE93-C63E-441E-AF94-B10D8017657AQ33604198-CC1EAB91-D22E-4481-88B4-ED5C6DA9C5BFQ33691741-D2FD6510-3552-4B51-BBE0-F82AA4B8B91FQ34270067-A88CEC46-F8D9-4D6D-9895-F9BED3A89A84Q34548568-AE4D08A3-0FC4-4F11-803F-C767D68F071EQ34681144-90BA67FF-09F3-4CC2-823A-C6C65E3FE792Q34802627-73615A4B-BE1B-4F51-9EDB-EC040C8AF1FAQ34981070-2A784164-F028-4C5D-B6F0-CDEA5C215D9DQ35060935-571702ED-76EF-4A7A-A697-B74BB72E80CDQ35242922-E0328E0A-7126-44ED-BB1F-81904C651FECQ35660695-D9BFA7B7-913D-48E5-BF0B-60249DDC8FE2Q36902083-5CEC90E4-1164-4233-854E-8C6645702D93Q36915364-DBB21D00-3040-4528-88D1-52CD5C9CAC4AQ36941523-7B59FD01-2699-4BF7-9D63-45DC9046C948Q37399669-BFD3B83E-F812-4A14-9B11-487A6CF1A064Q37547886-96986B0C-0ECA-46EA-ABB9-D0C4E584885EQ37895716-A0758EB5-5932-4EE8-B746-92E457224F1EQ38481495-5BC9C557-3B28-47B6-A53C-0340C3E673F2Q38598495-09179618-E047-432A-BB5F-5F958FB22787Q38937390-AB146F28-1ABE-485F-8BA1-7CFFECB43E06Q43592754-1ABE5535-9181-4762-A4C5-E21037175B98Q44030573-CC65404C-21EF-4A48-B454-54D6BE5E5323Q45176530-2942C58F-59CA-414E-A469-0E2D7EBA26CFQ48217471-83F0A787-8A1B-47B7-A630-074F457D21A8Q48379838-257681E9-0524-4873-9799-8C7384BDB2CAQ48827550-83395CFD-D489-481C-A9AC-8EB5D0D6AA5FQ50788766-F49FA77C-0E95-4E40-8949-75E81EBE62BEQ51079565-0D7853D1-8550-4040-AB6C-88B10E064B69Q51132750-8285DA51-2F4C-43F3-A17A-B749F59243CFQ52909097-D50DC27C-4692-499E-A571-2055E583C7F2
P2860
Testing the abuse liability of anxiolytic and hypnotic drugs in humans.
description
1991 nî lūn-bûn
@nan
1991 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
1991 թվականի հունիսին հրատարակված գիտական հոդված
@hy
1991年の論文
@ja
1991年論文
@yue
1991年論文
@zh-hant
1991年論文
@zh-hk
1991年論文
@zh-mo
1991年論文
@zh-tw
1991年论文
@wuu
name
Testing the abuse liability of anxiolytic and hypnotic drugs in humans.
@ast
Testing the abuse liability of anxiolytic and hypnotic drugs in humans.
@en
Testing the abuse liability of anxiolytic and hypnotic drugs in humans.
@nl
type
label
Testing the abuse liability of anxiolytic and hypnotic drugs in humans.
@ast
Testing the abuse liability of anxiolytic and hypnotic drugs in humans.
@en
Testing the abuse liability of anxiolytic and hypnotic drugs in humans.
@nl
prefLabel
Testing the abuse liability of anxiolytic and hypnotic drugs in humans.
@ast
Testing the abuse liability of anxiolytic and hypnotic drugs in humans.
@en
Testing the abuse liability of anxiolytic and hypnotic drugs in humans.
@nl
P1476
Testing the abuse liability of anxiolytic and hypnotic drugs in humans.
@en
P2093
Griffiths RR
P304
P356
10.1016/0376-8716(91)90054-3
P577
1991-06-01T00:00:00Z